Overview

A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia

Status:
Completed
Trial end date:
2010-10-02
Target enrollment:
Participant gender:
Summary
This Phase 1, double-blind (sponsor open) study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of ETC-1002 given to subjects with mild dyslipidemia.
Phase:
Phase 1
Details
Lead Sponsor:
Esperion Therapeutics
Esperion Therapeutics, Inc.
Treatments:
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid